X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SANOFI INDIA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SANOFI INDIA AUROBINDO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 15.6 32.9 47.5% View Chart
P/BV x 4.0 6.3 64.0% View Chart
Dividend Yield % 0.4 1.4 27.0%  

Financials

 AUROBINDO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
SANOFI INDIA
Dec-16
AUROBINDO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8954,560 19.6%   
Low Rs6224,400 14.1%   
Sales per share (Unadj.) Rs254.61,028.5 24.8%  
Earnings per share (Unadj.) Rs39.3129.0 30.5%  
Cash flow per share (Unadj.) Rs46.6186.0 25.0%  
Dividends per share (Unadj.) Rs2.5068.00 3.7%  
Dividend yield (eoy) %0.31.5 21.7%  
Book value per share (Unadj.) Rs160.0753.6 21.2%  
Shares outstanding (eoy) m585.8823.03 2,544.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.4 68.4%   
Avg P/E ratio x19.334.7 55.6%  
P/CF ratio (eoy) x16.324.1 67.6%  
Price / Book Value ratio x4.75.9 79.8%  
Dividend payout %6.452.7 12.1%   
Avg Mkt Cap Rs m444,390103,174 430.7%   
No. of employees `00014.03.6 385.9%   
Total wages/salary Rs m17,6783,592 492.1%   
Avg. sales/employee Rs Th10,667.86,537.7 163.2%   
Avg. wages/employee Rs Th1,264.3991.4 127.5%   
Avg. net profit/employee Rs Th1,645.8819.8 200.8%   
INCOME DATA
Net Sales Rs m149,15723,686 629.7%  
Other income Rs m1,159708 163.7%   
Total revenues Rs m150,31624,394 616.2%   
Gross profit Rs m34,3435,281 650.3%  
Depreciation Rs m4,2761,313 325.7%   
Interest Rs m66715 4,448.0%   
Profit before tax Rs m30,5584,661 655.6%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5971,691 449.2%   
Profit after tax Rs m23,0122,970 774.8%  
Gross profit margin %23.022.3 103.3%  
Effective tax rate %24.936.3 68.5%   
Net profit margin %15.412.5 123.0%  
BALANCE SHEET DATA
Current assets Rs m92,06215,673 587.4%   
Current liabilities Rs m66,2236,678 991.7%   
Net working cap to sales %17.338.0 45.6%  
Current ratio x1.42.3 59.2%  
Inventory Days Days10676 139.5%  
Debtors Days Days6822 303.3%  
Net fixed assets Rs m62,9198,098 777.0%   
Share capital Rs m586230 254.4%   
"Free" reserves Rs m93,13317,088 545.0%   
Net worth Rs m93,71917,356 540.0%   
Long term debt Rs m1,8140-   
Total assets Rs m162,49425,400 639.7%  
Interest coverage x46.8311.7 15.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 98.4%   
Return on assets %14.611.8 124.0%  
Return on equity %24.617.1 143.5%  
Return on capital %32.726.9 121.5%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m75,8387,145 1,061.4%   
Fx outflow Rs m30,2246,846 441.5%   
Net fx Rs m45,613299 15,255.3%   
CASH FLOW
From Operations Rs m32,7863,226 1,016.3%  
From Investments Rs m-17,870-1,555 1,149.2%  
From Financial Activity Rs m-19,153-1,818 1,053.5%  
Net Cashflow Rs m-4,239-147 2,883.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.0 14.4 55.2%  
FIIs % 27.7 14.6 189.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 15,184 458.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - DISHMAN PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS